[Integrase inhibition--a new mode of action in HIV therapy].
van Lunzen
Jan
J
Ambulanzzentrum, Bereich Infektiologie, Universitätsklinikum Hamburg-Eppendorf. v.lunzen@uke.uni-hamburg.de
Degen
Olaf
O
D019985:Benchmarking; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D018432:Drug Resistance, Multiple; D024882:Drug Resistance, Viral / Q000187:drug effects; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D011760:Pyrrolidinones / Q000009:adverse effects / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D019233:Retreatment; D019562:Viral Load
D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium